Last 47 quarters of trend data · Healthcare · Drug Discovery Platforms
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 38.33 | — | 213.68 | — | 24.73 | 26.82 | 36.99 | 47.13 | 152.67 | 160.41 | 64.03 | 336.56 | — | 231.05 | 3376.69 | 675.87 | 587.73 | 458.78 | 2567.43 | 8200.15 | 3838.00 |
| — | — | +477.7% | — | -83.8% | -83.3% | -42.2% | -86.0% | — | -30.6% | -98.1% | -50.2% | — | -49.6% | +31.5% | -91.8% | -84.7% | -19.6% | +442.4% | — | — | |
| P/B Ratio | 2.07 | 3.44 | 2.75 | 5.15 | 6.61 | 3.61 | 3.81 | 3.69 | 6.70 | 5.53 | 6.04 | 60.38 | 38.87 | 17.77 | 58.39 | 44.54 | 34.24 | 20.53 | 28.05 | 39.70 | 36.46 |
| — | -4.8% | -27.7% | +39.6% | -1.3% | -34.7% | -37.0% | -93.9% | -82.8% | -68.9% | -89.7% | +35.6% | +13.5% | -13.4% | +108.1% | +12.2% | -6.1% | -54.7% | -9.7% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.6% | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 98.5% | 100.0% | 100.0% | 100.0% | 96.8% | 100.0% | 83.6% | 85.2% | 83.8% | 62.9% | 81.3% | 79.2% | 59.9% | 34.5% |
| — | — | 0.0% | — | 0.0% | 0.0% | 0.0% | +1.8% | 0.0% | +19.6% | +17.3% | +15.5% | +59.0% | +2.8% | +7.7% | +40.0% | +82.1% | +15.2% | -5.8% | -23.4% | -61.7% | |
| Operating Margin | -1683.0% | — | -7259.5% | — | -1545.2% | -2155.4% | -1581.0% | -1463.0% | -2622.7% | -2074.9% | -460.7% | -753.0% | 31183.0% | -3089.6% | -6609.9% | -1734.7% | -1361.4% | -2425.2% | -4726.5% | -14434.3% | -4606.4% |
| — | — | -359.2% | — | +41.1% | -3.9% | -243.2% | -94.3% | -108.4% | +32.8% | +93.0% | +56.6% | +2390.6% | -27.4% | -39.8% | +88.0% | +70.4% | -92.8% | -721.6% | -5884.4% | -697.2% | |
| Net Margin | -1686.0% | — | -7249.9% | — | -1549.3% | -2177.6% | -1559.3% | -1470.0% | -2600.9% | -2121.1% | -448.0% | -779.6% | 36100.2% | -3051.9% | -6482.6% | -1796.6% | -1320.3% | -2389.7% | -4651.8% | -14359.9% | -3797.7% |
| — | — | -364.9% | — | +40.4% | -2.7% | -248.1% | -88.6% | -107.2% | +30.5% | +93.1% | +56.6% | +2834.3% | -27.7% | -39.4% | +87.5% | +65.2% | -90.7% | -2310.2% | -5999.7% | -610.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -232.0% | -37.7% | -27.0% | -44.8% | -69.4% | -63.5% | -33.6% | -31.7% | -25.1% | -22.4% | -13.6% | -39.0% | -36.9% | -54.7% | -24.6% | -25.9% | -17.7% | -23.7% | -12.6% | -16.2% | -10.1% |
| — | +40.6% | +19.6% | -41.2% | -176.4% | -183.4% | -146.2% | +18.6% | +31.9% | +59.0% | +44.5% | -50.5% | -107.9% | -131.0% | -95.5% | -59.3% | -75.6% | -1.7% | -310.3% | +49.8% | +59.9% | |
| ROA | -182.5% | -35.3% | -23.1% | -31.2% | -49.4% | -49.1% | -29.4% | -29.0% | -23.1% | -21.8% | -13.0% | -35.1% | -29.8% | -47.0% | -23.5% | -25.0% | -17.3% | -23.2% | -12.3% | -15.9% | -9.9% |
| — | +28.1% | +21.3% | -7.7% | -113.5% | -125.8% | -125.7% | +17.6% | +22.3% | +53.7% | +44.5% | -40.6% | -72.2% | -102.6% | -90.5% | -56.9% | -74.8% | -3.0% | -318.6% | +42.7% | +57.5% | |
| ROIC | -807.7% | -140.2% | -143.2% | -188.2% | -251.9% | -508.2% | -221.6% | -147.1% | -121.2% | -86.5% | -31.7% | -55.7% | -63.1% | -147.5% | -70.2% | -76.9% | -59.7% | -74.5% | -45.2% | -73.0% | -47.6% |
| — | +72.4% | +35.4% | -27.9% | -107.8% | -487.5% | -600.0% | -164.0% | -92.0% | +41.4% | +54.9% | +27.5% | -5.6% | -98.0% | -55.5% | -5.3% | -25.6% | +8.4% | -6.7% | -90.2% | -4.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.05 | 0.06 | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -11.5% | -17.0% | +61.9% | +134.2% | +54.3% | -24.4% | -69.7% | -70.7% | -66.2% | +285.7% | +588.2% | +834.2% | +466.7% | -9.7% | -12.7% | -12.1% | -26.1% | -29.4% | -90.6% | -88.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.32 | 10.60 | 26.88 | 3.68 | 2.32 | 3.90 | 4.24 | 29.64 | 7.18 | 58.27 | 66.29 | 21.63 | 8.22 | 4.01 | 17.94 | 19.04 | 35.96 | 40.09 | 63.86 | 45.86 | 81.18 |
| — | +171.7% | +534.2% | -87.6% | -67.7% | -93.3% | -93.6% | +37.0% | -12.6% | +1352.7% | +269.4% | +13.6% | -77.2% | -90.0% | -71.9% | -58.5% | -55.7% | -8.4% | +133.0% | +750.4% | +852.2% | |
| Quick Ratio | 2.32 | 10.60 | 26.88 | 3.68 | 2.32 | 3.90 | 4.24 | 29.64 | 7.18 | 58.27 | 66.29 | 21.63 | 8.22 | 4.01 | 17.91 | 19.00 | 35.76 | 39.89 | 63.67 | 45.75 | 80.99 |
| — | +171.7% | +534.2% | -87.6% | -67.7% | -93.3% | -93.6% | +37.0% | -12.6% | +1352.7% | +270.1% | +13.8% | -77.0% | -89.9% | -71.9% | -58.5% | -55.8% | -8.4% | +135.3% | +838.7% | +911.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LEXX stock.
Lexaria Bioscience Corp.'s current P/E is -1.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Lexaria Bioscience Corp.'s current operating margin is -1683.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Lexaria Bioscience Corp.'s business trajectory between earnings reports.